117 related articles for article (PubMed ID: 8976820)
1. The potential role of amifostine (Ethyol) in haematological malignancies.
Gorin NC
Eur J Cancer; 1996; 32A Suppl 4():S31-9. PubMed ID: 8976820
[TBL] [Abstract][Full Text] [Related]
2. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
[TBL] [Abstract][Full Text] [Related]
3. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects.
Douay L; Hu C; Giarratana MC; Gorin NC
Eur J Cancer; 1995; 31A Suppl 1():S14-6. PubMed ID: 7577094
[TBL] [Abstract][Full Text] [Related]
4. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
Fauth F; Martin H; Sonnhoff S; Bialleck H; Wiesneth M; Mihanovic B; Hoelzer D
Bone Marrow Transplant; 2000 Apr; 25(8):831-6. PubMed ID: 10808203
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
Jiang R; Bony V; Lopez M
Prog Clin Biol Res; 1994; 389():23-9. PubMed ID: 7700906
[No Abstract] [Full Text] [Related]
7. Use of amifostine in bone marrow purging.
Cagnoni PJ; Jones RB; Bearman SI; Ross M; Hami L; Franklin WA; Capizzi R; Schein PS; Shpall EJ
Semin Oncol; 1996 Aug; 23(4 Suppl 8):44-8. PubMed ID: 8783666
[TBL] [Abstract][Full Text] [Related]
8. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support.
Shpall EJ; Stemmer SM; Hami L; Franklin WA; Shaw L; Bonner HS; Bearman SI; Peters WP; Bast RC; McCulloch W
Blood; 1994 Jun; 83(11):3132-7. PubMed ID: 8193351
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
[TBL] [Abstract][Full Text] [Related]
10. Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation.
Makrynikola V; Kabral A; Bradstock KF
Bone Marrow Transplant; 1991 Nov; 8(5):351-5. PubMed ID: 1768969
[TBL] [Abstract][Full Text] [Related]
11. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
Skala JP; Rogers PC; Chan KW; Rodriguez WC
Prog Clin Biol Res; 1992; 377():57-62. PubMed ID: 1332075
[No Abstract] [Full Text] [Related]
12. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
Gidáli J; Fehér I
Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
[TBL] [Abstract][Full Text] [Related]
13. Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution.
Gorin NC; Labopin M; Laporte JP; Douay L; Lopez M; Lesage S; Fouillard L; Isnard F; Jouet JP; Bellal N; Perot C; Van Den Akker J; Bauters F; Najman A
Exp Hematol; 1999 Dec; 27(12):1822-30. PubMed ID: 10641600
[TBL] [Abstract][Full Text] [Related]
14. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants.
Douay L; Hu C; Giarratana MC; Gorin NC
Semin Oncol; 1994 Oct; 21(5 Suppl 11):16-20. PubMed ID: 7973773
[TBL] [Abstract][Full Text] [Related]
16. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
17. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT).
Gorin NC; Labopin M; Meloni G; Korbling M; Carella A; Herve P; Burnett A; Rizzoli V; Alessandrino EP; Bjorkstrand B
Leukemia; 1991 Oct; 5(10):896-904. PubMed ID: 1835746
[TBL] [Abstract][Full Text] [Related]
18. Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow.
Kramer B; Makrynikola V; Bradstock K
Prog Clin Biol Res; 1992; 377():41-7. PubMed ID: 1438438
[No Abstract] [Full Text] [Related]
19. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi RL; Scheffler BJ; Schein PS
Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery.
Poloni A; Leoni P; Curzi L; Cantori I; Mancini S; Montanari M; Masia MC; Olivieri A
Exp Hematol; 1999 Oct; 27(10):1548-56. PubMed ID: 10517497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
